120 related articles for article (PubMed ID: 20087881)
21. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Jazirehi AR; Vega MI; Bonavida B
Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
[TBL] [Abstract][Full Text] [Related]
22. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
Shringarpure R; Catley L; Bhole D; Burger R; Podar K; Tai YT; Kessler B; Galardy P; Ploegh H; Tassone P; Hideshima T; Mitsiades C; Munshi NC; Chauhan D; Anderson KC
Br J Haematol; 2006 Jul; 134(2):145-56. PubMed ID: 16846475
[TBL] [Abstract][Full Text] [Related]
23. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
24. Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma.
Wu G; Keating A
Cancer; 2006 Jan; 106(2):247-57. PubMed ID: 16342164
[TBL] [Abstract][Full Text] [Related]
25. Emerging therapies for B-cell non-Hodgkin lymphoma.
Briones J
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1305-16. PubMed ID: 19761434
[TBL] [Abstract][Full Text] [Related]
26. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
[TBL] [Abstract][Full Text] [Related]
27. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
28. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
[TBL] [Abstract][Full Text] [Related]
29. Interferon (IFN)-beta induces apoptotic cell death in DHL-4 diffuse large B cell lymphoma cells through tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Oehadian A; Koide N; Mu MM; Hassan F; Islam S; Yoshida T; Yokochi T
Cancer Lett; 2005 Jul; 225(1):85-92. PubMed ID: 15922860
[TBL] [Abstract][Full Text] [Related]
30. Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma.
Witkowska M; Smolewski P
Immunotherapy; 2015; 7(1):37-46. PubMed ID: 25572478
[TBL] [Abstract][Full Text] [Related]
31. Emerging drugs for diffuse large B-cell lymphoma.
Mondello P; Younes A
Expert Rev Anticancer Ther; 2015 Apr; 15(4):439-51. PubMed ID: 25652253
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies.
Hernandez-Ilizaliturri FJ; Czuczman MS
Oncology (Williston Park); 2009 Jun; 23(7):610-5. PubMed ID: 19626827
[TBL] [Abstract][Full Text] [Related]
33. Aberrant localization of apoptosis protease activating factor-1 in lipid raft sub-domains of diffuse large B cell lymphomas.
Hirpara JL; Loh T; Ng SB; Chng WJ; Pervaiz S
Oncotarget; 2016 Dec; 7(51):83964-83975. PubMed ID: 27863378
[TBL] [Abstract][Full Text] [Related]
34. Molecular pathogenesis in non-Hodgkin lymphoma: implications for therapy.
Vose JM
Transfus Apher Sci; 2013 Oct; 49(2):155-6. PubMed ID: 24051218
[TBL] [Abstract][Full Text] [Related]
35. Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma.
Kühnl A; Cunningham D; Chau I
Cancer Treat Rev; 2017 Sep; 59():132-137. PubMed ID: 28822237
[TBL] [Abstract][Full Text] [Related]
36. Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma.
Rhodes J; Landsburg DJ
Curr Hematol Malig Rep; 2018 Oct; 13(5):356-368. PubMed ID: 30112707
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of caspase 9 and not caspase 8 mediated apoptosis may determine clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas.
Oudejans JJ; Muris JJ; Meijer CJ
Cell Cycle; 2005 Apr; 4(4):526-8. PubMed ID: 15876872
[TBL] [Abstract][Full Text] [Related]
38. Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma.
Leveille E; Johnson NA
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946435
[TBL] [Abstract][Full Text] [Related]
39. Genetics of diffuse large B-cell lymphoma: paving a path to personalized medicine.
King RL; Bagg A
Cancer J; 2014; 20(1):43-7. PubMed ID: 24445764
[TBL] [Abstract][Full Text] [Related]
40. Diffuse large B cell lymphoma: molecular targeted therapy.
Roschewski M; Dunleavy K; Wilson WH
Int J Hematol; 2012 Nov; 96(5):552-61. PubMed ID: 23086603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
